Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-04
2006-07-04
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000, C548S183000, C548S226000, C548S317100
Reexamination Certificate
active
07071218
ABSTRACT:
The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:
REFERENCES:
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kühl et al.
patent: 4383529 (1983-05-01), Webster
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5223522 (1993-06-01), Clark et al.
patent: 5330998 (1994-07-01), Clark et al.
patent: 5512689 (1996-04-01), Quallich
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5650444 (1997-07-01), Cagiano et al.
patent: 5691376 (1997-11-01), Cagiano et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 6127415 (2000-10-01), Pfahl et al.
patent: 6262044 (2001-07-01), Møller et al.
patent: 6515003 (2003-02-01), Pfahl et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 6908939 (2005-06-01), Bernardon et al.
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 2005/0165072 (2005-07-01), Ayer et al.
patent: 0 212 617 (1987-03-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 343 643 (1989-11-01), None
patent: 1 048 659 (2000-11-01), None
patent: 1 142 885 (2001-10-01), None
patent: 55 038359 (1980-03-01), None
patent: WO 93/21146 (1993-10-01), None
patent: WO 94/12880 (1994-06-01), None
patent: WO 97/00249 (1997-01-01), None
patent: WO 97/03682 (1997-02-01), None
patent: WO 97/27191 (1997-07-01), None
patent: WO 99/09965 (1999-03-01), None
patent: WO 99/24415 (1999-05-01), None
patent: WO 99/58127 (1999-11-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/18748 (2000-04-01), None
patent: WO 00/32598 (2000-06-01), None
patent: WO 00/63196 (2000-10-01), None
patent: WO 00/066167 (2000-11-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/36402 (2001-05-01), None
patent: WO 02/12210 (2002-02-01), None
patent: WO 02/071827 (2002-09-01), None
patent: WO 02/072099 (2002-09-01), None
patent: WO 02/072543 (2002-09-01), None
patent: WO 02/080935 (2002-10-01), None
Acheson et al., “Two Hypothetical Metabolites of Proguanil,”J. Chem. Soc., 10:4727-4731 (1956).
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,”Cancer Res.48:589-601 (1988).
Aman et al., “The Inositol Phosphatase SHIP Inhibits Akt/PKB Activation in B Cells”J. Biol. Chem., 273(51)33922-33928 (1998).
Amin et al., “Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis,”Nitric pin. Rheumatol, 11(3):202-209 (1999).
Arakawa et al., “Novel Benzoxazole 2,4-Thiazolidinediones as Potent Hypoglycemic Agents. Synthesis and Structure-Acitivity Relationships,”Chem. Pharm. Bull., 42(12) 1984-1993 (1997).
Aranyos et al., “Novel Electron-Rich Bulky Phospine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,”J. Am. Chem. Soc.121:4369-4378 (1999).
Baraldi et al., “Exhaled Nitric Oxide Concentrations During Treatment of Wheezing Exacerbation in Infants and Young Children,”Am. J. Respir. Crit. Care Med., 159 (4 Pt. 1):1284-1288 (1999).
Beilstein Registry No. 29-30, 1975, Compound Registry No. 1120438.
Beilstein Registry No. 52, 1978, Compund Registry No. 4939128.
Bellacosa et al., “Structure, express and chromosomal mapping of c-akt: relationship to v-aktand its implications,”Oncongene, 8:745-754 (1993).
Black, “Simple Synthesis of 1-Azaadamantan-4-one,”Synthesis, 829-830 (1981).
Blakemore et al., “A Stereoselective Synthesis of trans-1,2-Disubstituted Alkenes Based on the Condensation of Aldehydes with Metallated 1-Phenyl-1H-tetrazol-5-yl Sulfones,”Synlett, 26-28 (1977).
Blondet et al., “Convenient Synthesis of 6-Methyl, 8-Methyl and 6,8-Dimethyl Derivatives of 5-Hydroxy-1,2,3,4-Tetrahydro-2-Quinolinone,”Organic Preparation and Procedures Int., 25(2):223-228 (1993).
Bradisher et al., “Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid,” J. Org. Chem., 15(2) 374-376 (1950).
Bredt et al., “Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme,”Proc. Natl. Acad. Sci.87:682-685 (1990).
Brennan et al., “Inhibitory Effect of TNFα Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis,”Lancet, 2:244-247 (1989).
Brown et al., “Purine Analogues as Amplifiers of Phleomycin. V* Thioethers of Several Heterocyclic Systems with One or Two Rings,” Aust. J. Chem 32: 2713-2726 (1979).
Bryant et al., “Host-Guest Complexation. 53. Functional Groups Preorganized in Hemispherands for Binding Alkali Metal and Ammonium Cations1,”J. Org. Chem., 55:4622-4634 (1990).
Cantello et al., “A Versatile Route to 2-Arylmethyl-1,2-oxadiazolidine-3,5-dionesviaRegiospecific Alkyl-ation of 1,2,4-Oxadiazolidine-3,5-dione,”Synlett, 263-264 (1997).
Cantello et al., “The Synthesis of BRL 49653—A Novel and Potent Antihyperglycaemic Agent,”Bioorganic&Medicinal Chemistry Letters, 4:1181-1184 (1994).
Caron et al., “Directed Ortho Metalation of Neopentyl Benzoates with LDA: Preparation of Arylboronic Acids,”J. Org. Chem., 63:2054-2055 (1998).
Cervantes et al., “Generation of oxindole-2-thiones (thiols) via dilithiated N-tert-Boc-anilines. Synthesis of a sulfur analog of MK8861,”Can. J. Chem., 73:336-342 (1995).
Chan et al., “New N- and O-Arylations with Phenyloboronic Acids and Curpric Acetate,”Tetrahedron Letters39:2933-2936 (1998).
Chang et al., “Transformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase,”Science, 276:(5320)1848-1850 (1997).
Chang et al., “The Upjohn Colony of KkayMice: A Model for Obese Type II Diabetes,”Elsevier Science Publishers B.V., Biomedical Division, Diabetes, pp. 466-470 (1986).
Charpentier et al., “Synthesis, Structure—Affinity Relationships, and Biological Activites of Ligands Binding to Retinoic Acid Receptor Subtypes,”J. Med. Chem.38:4993-5006 (1995).
Choi et al., “Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications for Carcinogenesis and Prevention,” Gut, 35:950-954 (1994).
Cobb et al., “N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,”J. Med. Chem.41:5055-5069 (1998).
Coleman “Diabetes-Obesity Syndromes in Mice,”Diabetes, 31(1):1-6 (Apr. 1982).
D'Amico, “Derivatives of 2-Benzothiazolesulfenamides. I. Novel Method for Preparation of N-Substituted Benzothizaolesulfenamides,” J. Org. Chem. 26:3436-3445 (1961).
Darses et al., “Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium Tetrafluoroborates with Aryl- and Alkenylboronic Acids,”Bull. Soc. Chem. Fr., 133:1095-1102 (1996).
Dawson et al., “Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity,”J. Med. Chemistry, 38:3368-3383 (1995).
Dawson et al., “The Synthetic Chemistry of Retinoids,”Biology, Chemistry, and Medicine, 2ndEdition, Raven Press, Ltd., New York (1994).
DeSimone et al., “Substituted 3-(2-Benzoxazyl)-benzimidazol-2-(1H)-ones: A New Class of GABAABrain Receptor Ligands,” Bioorganic & Medicinal Chemistry Letters 10:2723-2726 (2000).
Di Cristofano et al., “Pten and p27KIPIcooperate in prostate cancer tumor suppression in the mouse,”Nature Genetics, 27:222-224 (2001).
Dryanska et al., “a-Hydroxybenzylation and Benzylidenation of the Methyl Group in 2-Methyl-1,3-benzoxazole and 2-Methyl-1,3-benzothiazole,”
Al-Shamma Hussien A.
Boudjelal Mohamed
Fanjul Andrea N.
Pfahl Magnus
Pleynet David P. M.
Incyte San Diego Incorporated
Needle & Rosenberg P.C.
Ortho -McNeil Pharmaceutical, Inc.
Powers Fiona T.
LandOfFree
N-substituted heterocycles for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-substituted heterocycles for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-substituted heterocycles for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559661